Neurogene (NasdaqGM:NGNE) 2026 Conference Summary Company Overview - **Company**: Neurogene - **Focus**: Genetic medicines for devastating neurological diseases, particularly Rett syndrome - **Lead Program**: NGN-401 for the treatment of Rett syndrome, a severe disorder primarily affecting girls [3][4] Industry Context - **Market Opportunity**: Approximately 15,000-20,000 patients in the U.S. and major European markets, representing a multi-billion dollar market with limited current penetration [4] - **Gene Therapy Pricing**: Premium pricing expected for gene therapies, which may limit initial market penetration [4] Clinical Development - **Trial Status**: The Embolden registrational trial is ongoing, with multiple patients dosed before the end of the previous year. Enrollment and dosing are expected to complete in Q2 of the current year [5][19] - **Data Updates**: Phase 1/2 data from an 8-patient pediatric cohort announced in November, with a more comprehensive update expected mid-year [5] Efficacy and Outcomes - **Functional Gains**: The primary endpoint focuses on developmental milestones, with families and payers looking for functional gains rather than just single milestones. Multiple skill gains have been observed in patients, with no plateau in function noted so far [10][11] - **Durability of Benefits**: The therapy shows potential for durable gains over time, consistent with the biology of the disease [16] Delivery Method - **ICV Administration**: Intracerebroventricular (ICV) administration is a routine neurosurgical procedure, not seen as a barrier to adoption. It is performed by trained neurosurgeons and takes about one hour [18][20] - **Monitoring**: Post-procedure monitoring for potential toxicities is standard practice, similar to other gene therapies [21][22] Regulatory Considerations - **FDA Requirements**: The FDA requires at least 12 months of data for gene therapy approvals, which Neurogene is adhering to, avoiding the risk of a 6-month endpoint [27][28] - **Global Regulatory Path**: Currently focused on the U.S. market, with PRIME designation in Europe. Future updates on European regulatory engagement will be provided [33][34] Commercial Strategy - **Manufacturing Capacity**: Neurogene has in-house manufacturing capabilities in Houston, Texas, which will support the commercial launch without significant capital expenditures [30][31] - **Market Positioning**: The U.S. is the primary target market, with considerations for pricing strategies to ensure value is maintained without significant discounts in other regions [34][35] Patient Population and Eligibility - **Eligibility Criteria**: Patients with prior experience on other treatments like DAYBUE can qualify for gene therapy, provided they meet specific immunosuppression criteria [46][49] - **Market Demand**: There is a significant demand for treatment among families, with a focus on the urgency of access to gene therapy [51][54] Conclusion - Neurogene is advancing its lead program for Rett syndrome with a strong focus on clinical efficacy, regulatory compliance, and strategic market positioning. The company is well-prepared for the upcoming pivotal data and potential commercialization, addressing a significant unmet need in the patient population.

Group 1 - The core viewpoint of the article is that gene therapy is becoming a central focus for companies, with Hangzhou Jiayin Biotechnology Co., Ltd. officially submitting its prospectus to the Hong Kong Stock Exchange [1] - Jiayin Biotechnology, established in 2019, specializes in the development of gene therapies and oligonucleotide drugs, utilizing a dual technology platform system consisting of AAVarta and SODA [1] - The company’s research covers a wide range of diseases, including neurological disorders, ophthalmic diseases, and various hereditary and chronic conditions, resulting in a diversified product pipeline [1] Group 2 - Jiayin Biotechnology currently has 10 candidate products in development, with 4 of them already in clinical stages [2] - The core product EXG001-307, targeting SMA1 type, is set to enter Phase III clinical trials in the second half of this year and is considered the potential best-in-class candidate for SMA1 treatment in China [2] - The funds raised from the IPO will primarily be used for the further development of core products EXG001-307, key products EXG102-031 and EXG202, as well as to enhance the core technology platform and support daily operations and business expansion [2]

Domestic Financial Market - The National Development and Reform Commission is coordinating the development of charging infrastructure for new energy vehicles [5] - The Ministry of Civil Affairs is promoting the application of advanced technologies such as humanoid robots and brain-computer interfaces in the development of high-performance intelligent elderly care service robots [5] - The Ministry of Commerce is utilizing the China-US economic and trade consultation mechanism to manage differences and promote cooperation [5] Industry Latest Developments - Shenzhen is encouraging smart home systems to adapt to domestic systems and fully integrate AI, with related stocks including Ying Shi Innovation and Ruixin Microelectronics [7] - New gene therapy strategies are addressing the challenges of efficient delivery of long genes, with related stocks including Meibang Technology and Kaineng Health [7] - The surge in raw material prices and strong demand is leading to a price increase in electronic components, with related stocks including Jiang Hai Co. and Junwei Electronics [7] Focus on Listed Companies - Xinzhou Bang has submitted an application for listing on the Hong Kong Stock Exchange to strengthen its global supply layout for electronic chemicals [9] - Yunji Group plans to raise no more than 788 million yuan through a private placement to expand into intelligent manufacturing and overseas operations [9] - Lixing Co. intends to raise no more than 560 million yuan through a private placement to increase production capacity for high-end bearing rolling elements [9] - Bojie Co. is supplying liquid cooling testing equipment to N clients, with significant supply arrangements expected this year [9] Market Review and Outlook - On January 29, the three major indices showed mixed results, with the Shanghai Composite Index experiencing slight fluctuations and the Shanghai 50 Index rising over 1% [11] - The market saw rapid rotation of hotspots, with over 3,500 stocks declining, while the liquor sector surged in the afternoon [11] - The non-ferrous metals sector remained active, with copper and precious metals leading the gains, and the oil and gas sector continued its strong performance [11] - The real estate sector showed signs of rebound, while the chip industry faced declines [11] - Looking ahead, the market is expected to continue focusing on undervalued and high-certainty sectors, as the growth stocks are undergoing consolidation [11]

Core Viewpoint - AAVLINK is a novel gene therapy strategy developed by the Shenzhen Institute of Advanced Technology, which addresses the challenge of efficiently delivering long genes using AAV vectors, potentially advancing clinical applications for neurodevelopmental disorders and other genetic diseases [3][4]. Group 1: Background and Significance - Over 7,000 rare diseases have been identified globally, most of which are caused by genetic mutations and lack effective treatments, posing significant challenges in medicine [3]. - Gene therapy offers new hope for treating rare and hereditary diseases by repairing, replacing, or inhibiting pathogenic genes [3]. Group 2: AAVLINK Methodology - The AAVLINK method innovatively splits long genes into two segments, each packaged in separate AAV vectors; one carries a gene segment with a lox site, while the other carries the second segment and a Cre recombinase gene [4]. - Upon entering cells, the Cre recombinase recognizes the lox sites, allowing for precise reassembly of the split genes, leading to the expression of a full-length functional protein [4]. Group 3: Safety and Efficacy - AAVLINK 2.0 addresses potential issues of gene rearrangement and immune responses, enhancing the safety of clinical applications [4]. - Research indicates that this technology can efficiently reconstruct large gene segments in various cell types without producing truncated proteins, showing significantly higher recombination efficiency compared to traditional methods [4]. - Animal studies demonstrate that AAVLINK can effectively improve behavioral and epileptic phenotypes in relevant mouse models [4]. Group 4: Future Directions - The research team plans to further explore the systemic delivery efficiency of AAVLINK, investigate its mechanisms, and establish disease models, with aims for systematic validation in primate models and preclinical studies to facilitate the technology's translation into clinical practice [4].

Core Viewpoint - A new gene delivery method has been developed by a collaborative research team from the Shenzhen Institute of Advanced Technology and Peking University First Hospital, successfully enabling the safe and efficient delivery of long genes (11kb), which may advance gene therapy techniques for conditions such as autism and epilepsy [1] Group 1 - The new gene delivery method addresses the common challenge of delivering long genes effectively in gene therapy [1] - The research findings were published online on January 28 in the prestigious journal "Cell" [1] - The successful delivery of 11kb long genes represents a significant advancement in the field of gene therapy [1]

Core Insights - The article discusses a novel gene therapy strategy named "AAVLINK," which addresses the challenge of efficiently delivering long genes using AAV (adeno-associated virus) vectors, potentially advancing clinical applications for rare genetic diseases such as autism and epilepsy [1][2]. Group 1: AAVLINK Technology Development - The AAVLINK method allows for the efficient delivery of complete functional genes longer than 11kb by splitting them into two segments, each carried by separate AAVs, which then recombine inside target cells [2][3]. - This technology overcomes the limitations of traditional AAV delivery, which can only transport genes up to 4.7kb, thus expanding the potential for gene therapy in various genetic disorders [2][3]. Group 2: Research and Clinical Implications - The research team demonstrated that AAVLINK can reconstruct and restore the function of genes associated with autism (Shank3) and epilepsy (SCN1A) in animal models, leading to significant behavioral and phenotypic improvements [4][5]. - The team has created a comprehensive tool library for AAV long gene delivery, screening 193 long human pathogenic genes, which includes various diseases such as Duchenne muscular dystrophy and hereditary deafness, facilitating broader applications of the technology [4][5]. Group 3: Future Directions and Clinical Relevance - The AAVLINK platform is now open for use, allowing other research teams to focus on disease mechanisms and treatment optimization, thus enhancing the overall research landscape in gene therapy [5][6]. - The technology is expected to provide innovative solutions for treating difficult-to-manage pediatric epilepsy, addressing the root causes rather than just symptoms, which could significantly improve patient outcomes [6][7].

Core Insights - A research team from the Shenzhen Institute of Advanced Technology has developed a new gene therapy strategy called "AAVLINK," which addresses the challenge of efficiently delivering long genes using AAV (adeno-associated virus) vectors, potentially advancing clinical applications for gene therapies targeting neurological disorders like autism and epilepsy [1][2]. Group 1: Gene Therapy Development - The AAVLINK method innovatively splits long genes into two segments, each carried by separate AAVs, with one AAV containing a special "molecular magic tape" (lox site) and the other carrying the second gene segment along with the Cre recombinase gene [2]. - This approach allows for precise recombination of the split gene segments within target cells, enabling the expression of a complete functional gene [2]. - The technology has been shown to efficiently reconstruct large gene segments in various cell types without producing truncated proteins, demonstrating significantly higher recombination efficiency compared to traditional methods [2]. Group 2: Safety and Future Research - The research team has developed a 2.0 version of the AAVLINK technology that addresses potential issues related to gene rearrangement and immune responses, enhancing the safety of clinical applications [2]. - Animal studies indicate that this technology can effectively improve behavioral and epilepsy phenotypes in relevant mouse models [2]. - Future research will focus on exploring the systemic delivery efficiency of the technology, understanding its mechanisms, establishing disease models, and conducting preclinical studies in primate models to facilitate its practical application [2].

Core Viewpoint - The 2026 Chengdu High-tech Zone Industry-Capital Docking Conference aims to deepen the integration of capital and industry, focusing on the "3+6+6" modern industrial system to promote high-tech development and industrialization [2][3]. Group 1: Conference Overview - The conference will take place on January 14, 2026, at Chengdu Jingronghui, guided by the Chengdu High-tech Zone Management Committee and organized by various local financial and investment bodies [2]. - The event will feature the release of financing project lists and investment fund directions, establishing an efficient platform for industry-capital connections [2][3]. Group 2: Agenda Highlights - The agenda includes guest sign-in, opening remarks, and the release of the Chengdu High-tech Zone industry financing demand list and fund direction list [6]. - Keynote presentations will cover topics such as the Sichuan Provincial Guiding Fund System, advanced manufacturing fund, investment strategies in intelligent manufacturing, and the current state of China's biopharmaceutical industry [6][7]. Group 3: Project Roadshow - The conference will host a project roadshow featuring companies like Shanghai Xingsi Semiconductor Co., focusing on 5G/6G satellite internet, and Chengdu Haofu Technology Co., which specializes in high-end optoelectronic systems [7]. - Other participating companies include Guangdong Hanbang Laser Technology Co., Chengdu Yuetfan Innovation Technology Co., and Sichuan Zhishan Weixin Biotechnology Co., showcasing innovations in various high-tech fields [7].

Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative therapies, with a commitment to providing safe, effective, and affordable gene treatment solutions globally [3] - The company has developed a differentiated pipeline of rAAV gene therapy candidates, particularly targeting ophthalmic and cardiovascular diseases, with potential for global best-in-class status [1][3] Product Pipeline - As of the last feasible date (December 16, 2025), Frontera Therapeutics has eight rAAV gene therapy candidates, including two core products: FT-002 for X-linked retinitis pigmentosa (XLRP) and FT-003 for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [3] - The pipeline also includes a key product, FT-001, for treating RPE65 gene biallelic mutations leading to inherited retinal disease (IRD), along with five other candidates in preclinical and early stages targeting ophthalmic, cardiovascular, and neurological diseases [3] Competitive Advantages - The company boasts a differentiated gene therapy pipeline supported by robust clinical data and global best-in-class potential, utilizing its proprietary AAVANCETM Bac/Sf9 production platform for safe, scalable, and cost-effective high-quality production [5] - Frontera Therapeutics has established a strong translational medicine and clinical operations capability, with an agile and well-coordinated R&D team of 37 members across China and the U.S. [5] - The company has achieved 12 IND approvals from the National Medical Products Administration and the FDA, making it the leading developer of rAAV gene therapies in China [6] Financial Overview - For the fiscal year ending December 31, 2023, the company reported R&D expenses of approximately $27.585 million and a net loss of $35.860 million [7][8] - The projected R&D expenses for 2024 and the first nine months of 2025 are $20.576 million and $10.969 million, respectively, with net losses of $26.464 million and $13.311 million for the same periods [7][8] Industry Overview - The global gene therapy market is expected to reach $2.8 billion in 2024, with a compound annual growth rate (CAGR) of 312.9% from 2020 to 2024 [8] - The market is projected to grow at a CAGR of 24.7% from 2024 to 2035, reaching $32 billion by 2035 [8] - The Chinese gene therapy market is anticipated to grow significantly, with a projected CAGR of 53.4% from 2025 to 2035, reaching RMB 11.6 billion by 2035 [11] Market Potential for Ophthalmic Drugs - The global ophthalmic drug market is forecasted to grow from $33.5 billion in 2020 to $41.6 billion in 2024, with a CAGR of 5.6% [15] - The Chinese ophthalmic drug market is expected to grow from RMB 18.8 billion in 2020 to RMB 29.5 billion in 2024, with a CAGR of 11.9% [15]

Core Viewpoint - Frontera Therapeutics has submitted its listing application to the Hong Kong Stock Exchange, focusing on the development of innovative rAAV gene therapies, particularly for ophthalmic and cardiovascular diseases, with a differentiated pipeline showing global best-in-class potential [1][3]. Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company established in 2019, dedicated to developing safe, effective, and affordable gene therapy solutions for patients worldwide [3]. - The company's product pipeline includes eight rAAV gene therapy candidates, with two core products: FT-002 for X-linked retinitis pigmentosa and FT-003 for neovascular age-related macular degeneration and diabetic macular edema [3]. - The company has received 12 IND approvals from the National Medical Products Administration and the FDA, making it the leading developer of rAAV gene therapies in China [6]. Competitive Advantages - Frontera Therapeutics boasts a differentiated gene therapy pipeline supported by robust clinical data and global best-in-class potential [5]. - The company utilizes the AAVANCE Bac/Sf9 production platform for safe, scalable, and cost-effective high-quality production [5]. - It has a strong translational medicine and clinical operations capability, with an agile R&D team of 37 members across China and the U.S. [5]. Financial Overview - The company reported R&D expenses of approximately $27.6 million for the fiscal year 2023, with projected expenses of $20.6 million for 2024 [7]. - The net loss for the fiscal year 2023 was approximately $35.9 million, with a projected loss of $26.5 million for 2024 [8]. Industry Overview - The global gene therapy market is expected to reach $2.8 billion in 2024, with a compound annual growth rate (CAGR) of 312.9% from 2020 to 2024 [8]. - The Chinese gene therapy market is anticipated to grow at a CAGR of 53.4% from 2025 to 2035, reaching a market size of RMB 11.6 billion by 2035 [11]. - The global ophthalmic drug market is projected to grow from $33.5 billion in 2020 to $41.6 billion in 2024, with a CAGR of 5.6% [15].